Business
Zura Bio Enters into Sponsored Research Agreement with Benaroya Research Institute
Benaroya Research Institute to further characterize role of IL-7Rα in TSLP and IL-7 signaling pathways Agreement underscores Zura Bio’s commitment to
About this update from Zura Bio Limited
[{"type":"text","content":"\n\nBenaroya Research Institute to further characterize role of IL-7Rα in TSLP and IL-7 signaling pathways\n\n\n\nAgreement underscores Zura Bio’s commitment to advancing science in immune-mediated disorders\n\n\n\n HENDERSON, Nev.--(BUSINESS WIRE)--\nZura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, and Benaroya Research Institute (BRI), a Seattle based non-profit research institute within Virginia Mason Franciscan Health, announced that they have entered into a sponsored research agreement focused on further characterizing the pivotal role of Interleukin-7 receptor alpha (IL-7Rα) in Thymic Stromal Lymphopoietin (TSLP) and Interleukin-7 (IL-7) signaling pathways.\n\n\nZura Bio is currently advancing ZB-168, a monoclonal antibody targeting IL-7Rα, for the treatment of immune and inflammatory disorders. IL-7 and TSLP are important cytokines that play fundamental roles in regulating the development, differentiation, and maintenance of immune cells. This collaboration will further characterize the critical role for IL-7Rα in regulating these pathways and the potential impact on immune and inflammatory disorders.\n\n\nAt Benaroya Research Institute, this collaboration will leverage the expertise of Dr. Steve Ziegler, a world-renown authority in TSLP and IL-7 biology. Dr. Ziegler and his colleagues discovered that TSLP was instrumental in initiating the inflammatory cascade that leads to the development of asthma and other allergic diseases. Since then, the researchers also found TSLP to be critical in other immune system diseases. Dr. Ziegler has studied TSLP since 1993 and has developed many tools and strategies for studying the protein.\n\n\n\"We are thrilled to partner with the Benaroya Research Institute as we further explore the role of IL-7Rα in immune-mediated disorders,\" said Michael Howell, PhD, Chief Scientific Officer and Head of Translational Science at Zura Bio. “Dr. Ziegler's remarkable contributions to the field have significantly advanced the understanding of TSLP's role in immune responses. His presence within this collaboration adds a layer of scientific rigor and expertise to improve our understanding and pave the way for additional groundbreaking discoveries that can drive meaningful change...